Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Lifestyle Interventions May Be Needed to Improve MS Management, Quality of Life

December 10th 2021, 6:30pm


Changes to diet, wellness, and physical activity could have a profound effect on patients’ ability to manage their multiple sclerosis (MS) and significantly improve their quality of life at the same time, researchers concluded.

Rituximab Infusion Timing, Dosing and COVID-19 Hospitalization Not Linked, Study Says

December 1st 2021, 4:00pm


A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past research.

Millennials With Multiple Sclerosis: Are They Different or Has Medicine Evolved?

November 30th 2021, 9:00pm


On this episode of Managed Care Cast, hear from a multiple sclerosis (MS) specialist about how millennial patients are different (or not) in how they approach their disease.

BMI Not Found to Affect Cognitive Function, Brain Volume in Patients With RRMS

November 24th 2021, 5:08pm


Body mass index (BMI) was not identified as a factor influencing cognitive function or brain mass in patients with relapsing-remitting multiple sclerosis (RRMS), investigators of a recent analysis concluded.

Specific Growth Factor Found to Increase Risk of MS

November 23rd 2021, 2:30pm


In a study assessing the impacts of 5 growth factors on MS, fibroblast growth factor 23 was identified to increase the risk of patients experiencing the onset and progression of multiple sclerosis (MS).

European Commission Approves Biogen’s Vumerity as Oral RRMS Therapy

November 18th 2021, 8:30pm


The European Commission gave its stamp of approval for Vumerity (diroximel fumarate), developed by Biogen, as an oral treatment for patients with relapsing-remitting multiple sclerosis (RRMS).

Anti-CD20 Therapies May Increase Risk of Severe COVID-19 in Patients With MS

November 17th 2021, 3:30pm


Anti-CD20 disease-modifying therapies, including rituximab and ocrelizumab, were found to increase the risk of hospitalization and intensive care unit admission in patients with multiple sclerosis (MS) who develop COVID-19, investigators concluded in this new study.

Study Identifies Factors Influencing the Degree of Disability in MS

November 10th 2021, 9:35pm


Drug use, serum albumin, and total number of lesions may serve as independent factors influencing the degree of disability in patients with multiple sclerosis (MS), investigators of a retrospective analysis concluded.

Atypical Radiological, Lab Findings Linked to Choice of Therapy in Patients With MS

November 7th 2021, 6:45pm


Choice of therapy to manage multiple sclerosis (MS) and prevent relapse was found to influence radiological and laboratory results, including lesion presentation, giving insight into the paraclinical characteristics of patients receiving different MS therapies.

Patients With MS Have Similar Risks for COVID-19 Complications vs Other Populations

November 3rd 2021, 1:34pm


Patients with multiple sclerosis (MS) had similar factors associated with adverse COVID-19 outcomes vs other populations, but these risks were found to decrease with subsequent COVID-19 waves, investigators found.